<DOC>
	<DOC>NCT02016365</DOC>
	<brief_summary>The primary objective for this study is to evaluate the efficacy of doxycycline + ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR) subjects with cardiomyopathy with or without neuropathy.</brief_summary>
	<brief_title>Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amyloid Neuropathies, Familial</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Cardiomyopathy with septal thickness &gt; 15 mm and/or SNTProBNP &gt; 300 ng/ Age &gt;50 years Male and females after menopause. Menopause is defined as 6 to 12 months of amenorrhea in a woman over 45 years of age. Written informed consent to be obtained prior to any study procedure Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy of green birefringent material in Congo redstained tissue specimens, and typing of amyloid deposits as TTR and identification of amyloid fibril type. Molecular definition of the TTR mutation or immunohistochemical staining of amyloid fibrils with anti TTR antibody New York Heart Association (NYHA) class &lt;III Systolic blood pressure &gt;100 mmHg (standing) Must have symptomatic organ involvement with amyloid to justify therapy Liver transplantation in the previous 6 months or liver transplantation anticipated in less than 6 months; ALT and/or AST &gt; 2 x upper normal limit (UNL); Creatinine clearance &lt; 30 ml/min (Cockcroft Gault Formula) Any other lab values, illness or condition that in the opinion of the investigator might place the subject at unacceptable risk for participation in the study; History of hypersensitivity to any of the ingredients of the study therapies; Use of any investigational drug, device (or biologic) within 4 weeks prior to study entry or during the study.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Transthyretin amyloidosis</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>ATTR</keyword>
	<keyword>neuropathy</keyword>
</DOC>